NCT03146338View on ClinicalTrials.gov

Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)

NAUnknownINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

May 4, 2021

Study Completion Date

January 4, 2023

Conditions
Metastatic Colorectal CancerMetastatic Head and Neck Cancer
Interventions
OTHER

Magnesium-rich mineral water (Rozana)

intakes of 1.5 L by day

Trial Locations (12)

14000

Centre Maurice TUBIANA, Caen

22190

CARIO-HPCA Plérin, Plérin

37044

CHRU Tours, Tours

37175

CORT 37, Chambray-lès-Tours

54100

Polyclinique de Gentilly, Nancy

56100

GHBS Lorient, Lorient

72000

Centre Hospitalier, Le Mans

Centre Jean Bernard, Le Mans

79000

Centre Hospitalier, Niort

Unknown

Centre Hospitalier Départemental, La Roche-sur-Yon

Centre Hospitalier Centre Bretagne, Pontivy

Centre d'Oncolgie Saint Yves, Vannes

Sponsors

Collaborators (1)

Neptune
All Listed Sponsors
collaborator

Neptune

INDUSTRY

lead

Weprom

OTHER

NCT03146338 - Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) | Biotech Hunter | Biotech Hunter